Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Consolidated Net Income (2016 - 2025)

Collegium Pharmaceutical (COLL) has 10 years of Consolidated Net Income data on record, last reported at $45.0 million in Q4 2025.

  • For Q4 2025, Consolidated Net Income rose 259.21% year-over-year to $45.0 million; the TTM value through Dec 2025 reached $96.7 million, up 23.8%, while the annual FY2025 figure was $108.6 million, 15.75% up from the prior year.
  • Consolidated Net Income reached $45.0 million in Q4 2025 per COLL's latest filing, up from $31.5 million in the prior quarter.
  • Across five years, Consolidated Net Income topped out at $72.8 million in Q2 2021 and bottomed at -$25.0 million in Q4 2021.
  • Average Consolidated Net Income over 5 years is $14.2 million, with a median of $12.8 million recorded in 2023.
  • The widest YoY moves for Consolidated Net Income: up 7577.45% in 2021, down 459.79% in 2021.
  • A 5-year view of Consolidated Net Income shows it stood at -$25.0 million in 2021, then skyrocketed by 71.24% to -$7.2 million in 2022, then soared by 748.84% to $46.7 million in 2023, then crashed by 73.16% to $12.5 million in 2024, then skyrocketed by 259.21% to $45.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Consolidated Net Income were $45.0 million in Q4 2025, $31.5 million in Q3 2025, and $17.0 million in Q2 2025.